Spruce Biosciences Presented Results From Phase 2 POWER Study Of Tildacerfont For Polycystic Ovary Syndrome At The 2024 Annual Meeting Of The Endocrine Society
Portfolio Pulse from Benzinga Newsdesk
Spruce Biosciences presented positive Phase 2 POWER study results for Tildacerfont in treating Polycystic Ovary Syndrome at the 2024 Annual Meeting of the Endocrine Society. The study showed significant reductions in DHEAS and increases in SHBG, with no safety concerns.
June 03, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Spruce Biosciences' Phase 2 POWER study of Tildacerfont for Polycystic Ovary Syndrome showed significant reductions in DHEAS and increases in SHBG, with no safety concerns. This positive data could boost investor confidence and drive the stock price up in the short term.
The positive results from the Phase 2 POWER study, including significant reductions in DHEAS and increases in SHBG, along with no safety concerns, are likely to boost investor confidence in Spruce Biosciences. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100